FIGURE 4 Effects of prostanoid receptor antagonists, a tachykinin NK1 receptor antagonist, a bradykinin B2 receptor antagonist and a cyclooxygenase inhibitor on treprostinil (TRE) cough in guinea pigs. The compound (blue bars) or their respective vehicles (white bars) were administered intraperitoneally (30 min) or by aerosol (10 min) prior to nebulised TRE (3.30 μg·kg−1). Graphs show the mean±sem effects against TRE-induced cough of a) the IP receptor antagonist (RO 1138452, 10 mg·kg−1 i.p., n=5), the EP1 receptor antagonist (ONO-8711, 10 mg·kg−1 i.p., n=5–6), the EP2 receptor antagonist (PF-04418948, 5 mg·kg−1 i.p., n=5), the EP3 receptor antagonist (L-798106, 10 mg·kg−1 i.p., n=5–7) and the DP1 receptor antagonist (BW A868C 10 mg·kg−1 i.p., n=5); and b) the NK1 receptor antagonist (CP99994, 10 mg·kg−1, i.p., n=5), the bradykinin B2 receptor antagonist (HOE 140, 1 mg·mL−1 delivered by aerosol, n=3) and the cyclooxygenase (COX) inhibitor (meclofenamic acid, 1 mg·kg−1 i.p., n=3). *: p<0.05 compared to vehicle.